To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in the era of highly active antiretroviral therapy (HAART), trends in causes of death among persons with AIDS in San Francisco who died between 1994 and 1998 were analyzed. Among 5234 deaths, the mortality rate for human immunodeficiency virus (HIV)-related or AIDS-related deaths declined after 1995 ( ), whereas the mortality rate for non-HIV-P ! .01 or non-AIDS-related deaths remained stable. The proportion of deaths of persons with AIDS associated with septicemia, non-AIDS-defining malignancy, chronic liver disease, viral hepatitis, overdose, obstructive lung disease, coronary artery disease, and pancreatitis increased ( ). The standardized mortality ratio was high for these causes in both pre-and post-P ! .05 HAART periods, except for pancreatitis, a possible complication of HAART, which demonstrated an increasing standardized mortality ratio trend after 1996. With increasing AIDS survival, prevention of chronic diseases, assessment of long-term toxicity from HAART, and surveillance for additional causes of mortality will become increasingly important.
certificates, reports from the State Office of AIDS, and annual matches with the National Death Index.
All deaths among persons aged 112 years who were given an AIDS diagnosis in San Francisco between 1 January 1994 through 31 December 1998 were included in the analysis. Cause-of-death information, as determined by death certificate review, was coded by use of the International Classification of Diseases-9th revision (ICD-9) [5] . We examined trends in both underlying and contributory causes of death that occurred in at least 1% of the deaths during the 5-year study period. HIV-or AIDS-related causes of death were defined as causes of death identified by ICD-9 codes 042-044, as well as for all AIDS-related opportunistic infections as defined by CDC criteria [3] . In addition, trends in syndromes associated with mitochondrial toxicity (lactic acidosis, acute hepatitis not otherwise specified, polyneuropathy, myopathy, myocarditis, cardiomyopathy, pancreatitis, and adverse drug reaction) were evaluated.
We analyzed the temporal trends among AIDS deaths in 3 ways. First, we compared annual changes in the proportion of underlying and contributory causes of deaths combined due to each cause by use of the Mantel-Haenszel x 2 test. Second, we calculated the trends in the mortality rates for HIV-or AIDS-related and non-HIV-or non-AIDS-related deaths by use of the x 2 test for linear trend. The single underlying cause of death was used for the numerator, and the denominator included the number of persons living with AIDS and the number of persons with AIDS who died in each year. Third, we compared trends in the observed number of deaths due to selected non-HIV-or non-AIDS-related causes, with the expected number of deaths derived from a reference population adjusted by race and age. Because of sample size constraints, this analysis was limited to men. We used the underlying cause of death and the indirect standardization method in which the standard population was California men aged 20-79 years. We calculated the standardized mortality ratio by dividing the number of observed deaths by the number of expected deaths. All statistical tests were done with use of SAS software (SAS Institute) and EpiInfo (CDC).
Results
There were 5234 deaths among persons with AIDS in San Francisco from 1 January 1994 through 31 December 1998. The demographic and risk characteristics of the deaths were similar to those of persons living with AIDS in the same time period, occurring mostly among men (96%), whites (71%), and men who have sex with men (men who have sex with men as the only risk, 74%; men who have sex with men and who also inject drugs, 14%). The median age at time of death increased from 40 years for persons with AIDS dying in 1994 to 44 years for persons with AIDS dying in 1998. Twenty causes listed as the underlying or contributory cause of death occurred in at least 1% of deaths during the study period (table 1) . There was a decline in the proportion of deaths associated with HIV-or AIDS-related causes between 1994 and 1998 and an increase in the proportion of deaths associated with non-HIV-or non-AIDS-related causes.
Among causes of death associated with AIDS-related opportunistic infections, there were statistically significant declines in the proportion associated with nontuberculous mycobacteria, wasting syndrome, cytomegalovirus infection, Pneumocystis carinii pneumonia, Kaposi sarcoma, progressive multifocal leukoencephalopathy, toxoplasmosis, and cryptosporidiosis (P ! ). There was a small increase of borderline significance for .01 non-Hodgkin lymphoma ( ). P ! .08 Of the non-HIV-or non-AIDS-related causes of death, the proportion of deaths associated with malignancies other than Kaposi sarcoma or non-Hodgkin lymphoma, viral hepatitis, chronic liver disease, coronary artery disease, obstructive lung disease, septicemia, and overdose increased significantly (P ! ). Of the causes of death that might represent mitochondrial .05 toxicity, pancreatitis and cardiomyopathy were found to occur ). P ! .01 Annual changes in mortality rates are shown in figure 1 . Decreases in all-cause mortality as well as mortality due to HIVor AIDS-related conditions were observed from 1995 through
(
). Death rates due to non-HIV-or non-AIDS-P ! .01 related causes remained relatively stable ( ). P p . 15 The numbers of observed and expected deaths due to selected non-HIV-or non-AIDS-related causes are shown in table 2. For the pooled years 1994-1998, the observed number of deaths exceeded the expected number for every cause examined. The ratio of observed to expected number of deaths (the standardized mortality ratio) was highest for viral hepatitis, septicemia, and pancreatitis.
Discussion
As others have reported, we found a decline in the rate of HIV-or AIDS-related deaths from 1995 through 1998 [1, 2] . The relatively stable rate seen between 1997 and 1998 likely reflects a plateau and subsequent leveling off of the beneficial effects of HAART in this population. Also consistent with other studies, we found an increasing proportion of deaths from 1994 through 1998 associated with non-AIDS-defining malignancies and other chronic diseases [1, 2] . Furthermore, the observed numbers for these causes of death in our study population exceeded the expected numbers derived from an age-and race-adjusted reference population in both pre-and post-HAART eras.
The increased prominence of deaths associated with overdoses, viral hepatitis and end-stage liver disease, obstructive lung disease, and septicemia suggests that risk behaviors that may be more prevalent in HIV-infected persons are playing an important role in mortality trends. Coinfection with HIV and the hepatitis viruses is common and may accelerate the progression of liver disease. Prevalence rates of HBV-induced cirrhosis are higher in the presence of HIV infection, and HIV-and HCV-coinfected patients have more rapid progression to fibrosis and liver failure and an increased risk of death [6] . Although recent reports have suggested that HAART may contribute to hepatotoxicity irrespective of presence of coinfection with HBV or HCV [7] , we found no evidence for an increase in observed compared with expected numbers of deaths due to liver disease after the first 2 years of widespread use of HAART. The importance of deaths associated with septicemia was not surprising, given the association between HIV and injection drug use, a behavior that conveys an increased risk of death due to these and other causes independent of HIV serostatus [8] . Obstructive lung disease, chronic bronchitis, and bronchiectasis have been reported to occur at increased frequencies among HIV-infected persons, and infection with HIV may accelerate the onset of smoking-induced emphysema [9] . Smoking prevalence is high among HIV-infected persons [10] , as well as among men who have sex with men [11] , who contributed 170% of deaths in our study. The importance of tobacco exposure as a mediator is supported by our finding that lung cancer was the most common cause of death from non-AIDS-defining malignancies, followed by Hodgkin disease, liver cancer, and anal cancer. Almost half of the hepatocellular cancer deaths were associated with HBV and HCV. Other risk factors, such as tobacco, alcohol, or coinfection with sexually transmitted viruses, may also contribute to the pathogenesis of these diverse cancers. The role that HIV plays in inducing these varied cancers is unclear but may be related to defects in immunosurveillance with advancing immunosuppression, chronic B cell stimulation, deregulation of cytokine pathways, and individual host genetic susceptibility-pathogenetic mechanisms that might occur in the early stages of immune deficiency, when antiretroviral therapy is commonly not given and also may have little, if any, modulating effect.
Risk factors such as tobacco or noninjection drug use may have also played a role in the increasingly higher proportion of deaths associated with coronary artery disease. However, primary HIV infection may also contribute to higher rates of baseline coronary heart disease [12] . More recently, frequent observations of fat redistribution, lipid disorders, and insulin resistance have focused attention on the potential for HAART to increase cardiovascular morbidity. These concerns are supported by findings of higher rates of coronary events in HIV-infected persons with longer duration of protease inhibitor use after adjustment for other cardiac risk factors [13] . Our data are insufficient to demonstrate an effect of HAART on cardiac deaths in the short term, but we note that the highest number of deaths occurred in 1998. Whether that single increase indicates a trend will require additional years of data to determine.
Finally, we found an increasing proportionate mortality associated with pancreatitis and, to a lesser extent, cardiomyopathy. We were unable to control for alcohol consumption, which may have contributed to these deaths, but the trend toward increasing standardized mortality ratios after 1996 is intriguing. Dilated cardiomyopathy in the setting of HIV infection associated with chronic zidovudine use has been observed in children [14] . An association with long-term didanosine and lamivudine use and pancreatitis is well described [15] , and hypertriglyceridemia, an adverse effect of protease inhibitors, is a strong risk factor for pancreatitis. Because of the lack of reported case series, further studies with longer follow-up are required before firm conclusions can be drawn about these potential life-threatening complications of HAART.
Our study has several limitations. The quality of our data depends on how accurately and thoroughly the causes of death were reported on death certificates. Underreporting of deaths due to HIV-or AIDS-related causes (e.g., stemming from concerns for patient confidentiality) or overreporting of deaths due to HIV-or AIDS-related causes (e.g., when the cause of death is stated to be end-stage AIDS, a broad, nonspecific descriptor that includes a mix of difficult-to-diagnose or unidentified disease processes) can occur. Our data are limited to a population in which the majority of HIV infections are sexually acquired, and, thus, we may have not detected mortality trends that occur predominantly among injection drug users. By including only persons with AIDS in our analysis, we may have missed important mortality trends among persons at earlier stages of HIV infection. Finally, our study follows patients only through 1998, which may not allow enough time to fully assess mortality trends resulting from the widespread use of HAART.
In conclusion, although the mortality rate due to many HIVor AIDS-related conditions has declined, the mortality rate attributed to non-AIDS-defining malignancies, chronic diseases, and complications of injection drug use has remained stable, although these causes now make up a higher proportion of overall deaths among persons with AIDS. The small but increasing trend for deaths due to pancreatitis suggest that adverse effects from HAART may be contributing to increased mortality.
